Piper Sandler raised the firm’s price target on Hims & Hers to $24 from $21 and keeps a Neutral rating on the shares. Heading into the new year, the firm is watching the impact of rates and lending standards across its coverage, as well as the influence of the new administration, including tax policy, potential tariffs, and appointee beliefs. Piper believes it’s prudent to favor GARP and value with a strong focus on fundamentals, but does feel comfortable paying a bit of a higher price if those fundamentals align.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HIMS:
- BofA says Hims’ semaglutide compounding opportunity may be shorter than expected
- End to tirzepatide shortage has read on Hims GLP-1 trajectory, says Leerink
- Hims & Hers falls after FDA ends shortage of Lilly weight loss drug
- Hims & Hers falls -12.0%
- Unusually active option classes on open December 19th